Lead candidate AMC303 is being developed as a treatment for patients with advanced and metastatic squamous tumors, e.g. head and neck cancer, esophageal cancer, cervical cancer, and lung cancer. AMC303 has a high specificity for inhibiting CD44v6, a co-receptor required for signaling through multiple cellular pathways (c-Met, VEGFR-2, RON)
Employees: 1-10
Total raised: $8.39M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | LBBW Ventu... | lbbwvc.de |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 31.08.2017 | Grant | $2.08M | - |
| 14.12.2016 | Series B | $6.31M | - |
Mentions in press and media 4
| Date | Title | Description |
| 31.08.2017 | amcure Receives Additional €1.75M Research Grant | amcure, a German biopharmaceutical company developing cancer therapeutics, received approval of a new approximately €1.75m grant by the German Ministry of Education and Research (BMBF). The grant covers a portion of the investment needed to... |
| 15.12.2016 | Amcure raises €6M in Series B, takes on Roche alumnus as new board member | German oncology biotech Amcure has secured a €6 million pot for its second formal round of funding as it looks to speed up the development of its leading candidate, AMC303. The funding comes from a group of existing investors, headed up by ... |
| 14.12.2016 | Term Sheet — Wednesday, December 14 | SAN DIEGO, DIVERSITY AND LEONARDO DICAPRIO Stars, They’re Just Like Us: Yesterday’s Term Sheet included an item about Leonardo DiCaprio joining Boston venture capital firm Data Point Capital as an advisor. Since a few readers asked about it... |
| 14.12.2016 | amcure Raises €6M in Series B Financing | amcure, an Eggenstein-Leopoldshafen, Germany-based biopharmaceutical company developing cancer therapeutics, closed a €6m Series B financing round. The round was led by LBBW Venture Capital, with participation from the KfW, MBG Mittelstaend... |